Concordance targets pro-inflammatory compounds with our synthetic biology
----Justin Hayes, Founder & CEO
Concordance targets pro-inflammatory compounds with our synthetic biology
----Justin Hayes, Founder & CEO
First Metabolite-Based IBD Therapy
We are a first in class metabolite-based therapeutic platform for IBD treatment.
We at Concordance Therapeutics are proud to introduce the first metabolite-based therapeutic platform for treating inflammatory bowel disease (IBD). While traditional therapeutics like aminosalicylates, immunomodulators, corticosteroids, and biologics have long been the standard, and microbial therapies have explored consortia-based and engineered approaches, we are redefining the landscape with our innovative, metabolite-based solutions. By reinventing "smart bugs," we are leading a new era in IBD treatment that offers a targeted, effective alternative to current methods.
Innovative Therapies Targeting Pro-Inflammatory Gut Metabolites
At Concordance Therapeutics, we target pro-inflammatory gut metabolites that drive disease and lack effective treatments. Our approach links gut-derived metabolites to conditions like inflammatory bowel disease (IBD) and metabolic disorders, making these metabolites key therapeutic targets.
Our "smart bacteria" localize to disease sites in the gut, consuming toxic metabolites and converting them into anti-inflammatory compounds. Our synthetic biology platform, focused on engineering and validating bacterial strains, initially targets IBD but also has potential for cardiometabolic diseases and diabetes.
About Concordance Tx
We at Concordance Therapeutics are pioneering a first-in-class metabolite-based therapy that targets hydrogen sulfide (H₂S), a key pro-inflammatory molecule implicated in inflammatory bowel disease (IBD). Our lead product candidates, CTX101 and CTX102, are designed to revolutionize IBD treatment by leveraging microbial metabolites to degrade harmful pro-inflammatory molecules and synthesize beneficial anti-inflammatory compounds.
In early clinical trials, CTX102 has shown promise by significantly reducing intestinal H₂S levels, which is associated with decreased inflammation and improved gut health. Beyond IBD, we envision broader applications for our platform in conditions like cardiometabolic diseases and diabetes, offering a new approach to address inflammation and metabolic imbalance for millions of patients.
4o
Meet the Team
Justin Hayes
Andrew Zorn, M.S.
Andrew Zorn, M.S.
CEO & Founder
Ph.D. Candidate
Northeastern University
Andrew Zorn, M.S.
Andrew Zorn, M.S.
Andrew Zorn, M.S.
Co-Founder
10 years Drug Discovery
Ph.D. Candidate
Northeastern University
Calvin Johnson
Andrew Zorn, M.S.
Calvin Johnson
Co-Founder
5 years Biotech Startup Exp.
Ph.D. Candidate
UMass Chan Medical School
SAB
Dr. Benjamin Woolston
Dr. Benjamin Woolston
Dr. Benjamin Woolston
Co-Founder & SAB
Assistant Professor
Northeastern University
Dr. Ryan Koppes
Dr. Benjamin Woolston
Dr. Benjamin Woolston
Co-Founder & SAB
Associate Professor
Northeastern University
Brand Background
Concordance Therapeutics has achieved significant milestones in developing its engineered therapeutic, CTX101. Starting with an NSF Trailblazer grant of $628,000 in September 2022, the company filed a provisional patent in September 2023. A key publication on hydrogen sulfide (H₂S) will be released in Cell Reports in November 2023. In January 2024, Concordance Therapeutics will officially be established, with in vivo studies for CTX101 beginning in May 2024. The company has also secured support from MassChallenge, Portal Innovations, and Pillar's Frequency Bio cohort for further development.
NIH Trailblazer Award for Engineering Smarter Gut Metabolites To Affect Human Health
ChE Assistant Professor Benjamin Woolston is leading a $628K NIH Trailerblazer Award with Assistant Professor Ryan Koppes, Associate Professor Abigail Koppes, and Professor Rebecca Carrier for “Engineered Probiotics for Closed-Loop Control of Disease-Associated Gut Metabolites in Gut-On-Chip Models.”
Cell Report: Engineered bacteria titrate hydrogen sulfide and induce concentration-dependent effects
Our Promise
Concordance Therapeutics strives to enhance patient care by developing innovative therapies that not only address current health challenges but also preserve the long-term efficacy of critical treatments like antibiotics. By focusing on targeted, metabolite-based approaches, we aim to reduce the overuse and misuse of antibiotics, which are key drivers of antimicrobial resistance. Our mission is to provide sustainable solutions that improve patient outcomes while safeguarding the effectiveness of antibiotics for future generations, ensuring they remain a cornerstone of modern medicine for years to come.